Marta Mosca

29.5k total citations · 4 hit papers
311 papers, 7.7k citations indexed

About

Marta Mosca is a scholar working on Rheumatology, Pathology and Forensic Medicine and Immunology. According to data from OpenAlex, Marta Mosca has authored 311 papers receiving a total of 7.7k indexed citations (citations by other indexed papers that have themselves been cited), including 193 papers in Rheumatology, 83 papers in Pathology and Forensic Medicine and 73 papers in Immunology. Recurrent topics in Marta Mosca's work include Systemic Lupus Erythematosus Research (151 papers), Systemic Sclerosis and Related Diseases (63 papers) and Monoclonal and Polyclonal Antibodies Research (46 papers). Marta Mosca is often cited by papers focused on Systemic Lupus Erythematosus Research (151 papers), Systemic Sclerosis and Related Diseases (63 papers) and Monoclonal and Polyclonal Antibodies Research (46 papers). Marta Mosca collaborates with scholars based in Italy, United States and Germany. Marta Mosca's co-authors include Stefano Bombardieri, Chiara Tani, R Neri, Chiara Baldini, Linda Carli, Caroline Gordon, Bridget Griffiths, S Bombardieri, Rosaria Talarico and Michelle Petri and has published in prestigious journals such as The Lancet, The Journal of Experimental Medicine and SHILAP Revista de lepidopterología.

In The Last Decade

Marta Mosca

292 papers receiving 7.6k citations

Hit Papers

align trajectories sort by overperformance

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

An official European Respiratory Society/American Thoracic Society research statement: interstitial pneumonia with autoimmune features

2015 655 citations Marta Mosca et al. profile →
Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 2 trial

2018 356 citations Marta Mosca et al. profile →
Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 3 trial (SLE-BRAVE-II)

2023 89 citations Marta Mosca et al. profile →
Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 3 trial (SLE-BRAVE-I)

2023 79 citations Marta Mosca et al. profile →

Author Peers

Peers are selected by citation overlap in the author's most active subfields. citations · hero ref

Author						Papers	Cites
Marta Mosca	4.4k	2.5k	1.6k	1.4k	1.1k	311	7.7k
Alexandre E. Voskuyl	5.6k 1.3×	2.2k 0.9×	1.6k 1.0×	800 0.6×	1.2k 1.1×	246	9.2k
David D’Cruz	6.5k 1.5×	4.0k 1.6×	1.2k 0.8×	989 0.7×	1.6k 1.5×	279	10.8k
Panayiotis G. Vlachoyiannopoulos	5.4k 1.2×	1.8k 0.7×	1.4k 0.9×	550 0.4×	865 0.8×	118	8.2k
Gerard Espinosa	5.4k 1.2×	1.8k 0.7×	844 0.5×	702 0.5×	1.2k 1.1×	340	8.8k
Solbritt Rantapää‐Dahlqvist	8.4k 1.9×	3.7k 1.5×	1.1k 0.7×	911 0.6×	958 0.9×	248	12.6k
Earl D. Silverman	6.5k 1.5×	3.3k 1.3×	930 0.6×	1.2k 0.9×	1.4k 1.2×	258	12.1k
Martin Aringer	4.1k 0.9×	3.0k 1.2×	991 0.6×	718 0.5×	1.3k 1.2×	232	7.5k
Tatsuya Atsumi	9.5k 2.1×	4.2k 1.7×	1.2k 0.8×	1.2k 0.8×	1.5k 1.4×	512	15.5k
Carl Turesson	4.6k 1.1×	1.2k 0.5×	702 0.4×	632 0.4×	1.5k 1.4×	170	6.6k
Pilar Brito‐Zerón	3.3k 0.7×	1.9k 0.7×	909 0.6×	1.4k 1.0×	1.1k 1.0×	120	8.8k

Countries citing papers authored by Marta Mosca

Since Specialization

Citations

This map shows the geographic impact of Marta Mosca's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Marta Mosca with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Marta Mosca more than expected).

Fields of papers citing papers by Marta Mosca

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Marta Mosca. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Marta Mosca. The network helps show where Marta Mosca may publish in the future.

Co-authorship network of co-authors of Marta Mosca

This figure shows the co-authorship network connecting the top 25 collaborators of Marta Mosca. A scholar is included among the top collaborators of Marta Mosca based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Marta Mosca. Marta Mosca is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Zucchi, Dina, Elena Elefante, Viola Signorini, et al.. (2024). Environment and systemic lupus erythematosus. Clinical and Experimental Rheumatology. 42(5). 1104–1114. 4 indexed citations

Sciascia, Savino, Marta Calatroni, Vincenzo L’Imperio, et al.. (2024). O25 Lupus podocytopathy: a rare form of lupus nephritis – an Italian retrospective multicenter study. SHILAP Revista de lepidopterología. A26–A27.

Tani, Chiara, Viola Signorini, Dina Zucchi, et al.. (2024). When is the right time to change therapy? An observational study of the time to response to immunosuppressive drugs in systemic lupus erythematosus. Lupus Science & Medicine. 11(2). e001207–e001207.

Tani, Chiara, Dina Zucchi, Elena Elefante, et al.. (2024). Analysis of belimumab prescription and outcomes in a 10-year monocentric cohort: is there an advantage with early use?. RMD Open. 10(2). e003981–e003981. 4 indexed citations

Elefante, Elena, Davide Schiliró, Viola Signorini, et al.. (2024). Impact of disease activity patterns on health-related quality of life (HRQoL) in patients with systemic lupus erythematosus (SLE). Lupus Science & Medicine. 11(2). e001202–e001202. 5 indexed citations

Rocca, Gaetano La, Francesco Ferro, Gianluca Sambataro, et al.. (2024). Interstitial Lung Disease Phenotypes and Predictive Risk Factors in Primary Sjögren’s Syndrome. Journal of Clinical Medicine. 13(16). 4963–4963. 2 indexed citations

Mosca, Marta, et al.. (2023). LRP5 high bone mass (Worth-type autosomal dominant endosteal hyperostosis): case report and historical review of the literature. Archives of Osteoporosis. 18(1). 112–112. 3 indexed citations

Palla, Ilaria, Valentina Lorenzoni, Salvatore Pirri, et al.. (2023). Exploring disease perception in Behçet’s syndrome: combining a quantitative and a qualitative study based on a narrative medicine approach. Orphanet Journal of Rare Diseases. 18(1). 58–58. 4 indexed citations

Convertino, Irma, Massimiliano Cazzato, Rosa Gini, et al.. (2023). Assessing disease activity of rheumatoid arthritis patients and drug-utilization patterns of biologic disease-modifying antirheumatic drugs in the Tuscany region, Italy. Frontiers in Pharmacology. 14. 1244486–1244486.

10.

Zucchi, Dina, et al.. (2023). Adherence to medication during pregnancy in systemic autoimmune diseases: results from a prospective study. Clinical and Experimental Rheumatology. 42(3). 666–670. 1 indexed citations

11.

Trentin, Francesca, Chiara Tani, Alberto Cauli, et al.. (2023). AB0558 ANIFROLUMAB IN REFRACTORY SYSTEMIC LUPUS ERYTHEMATOSUS: A REAL-LIFE, MULTICENTER STUDY. Annals of the Rheumatic Diseases. 82. 1476–1476. 2 indexed citations

12.

Fulvio, Giovanni, et al.. (2023). POS1461 ADVANTAGES OF DOPPLER IN LABIAL SALIVARY GLAND ULTRA-HIGH FREQUENCY ULTRASOUND: CORRELATIONS WITH HISTOLOGICAL INFLAMMATION, pSS DIAGNOSIS, DISEASE ACTIVITY, AND PROGNOSIS. Annals of the Rheumatic Diseases. 82. 1085–1085. 1 indexed citations

13.

Sedie, Andrea Delle, et al.. (2023). AB1020 MUSCULOSKELETAL INVOLVEMENT IN INFLAMMATORY BOWEL DISEASE PATIENTS: A MONOCENTRIC EXPERIENCE. Annals of the Rheumatic Diseases. 82. 1732–1732. 1 indexed citations

14.

Mattia, G. De, et al.. (2023). AB1258 CAMURATI-ENGELMANN DISEASE: EFFICACY OF ANTI-TNFALFA TREATMENT. Annals of the Rheumatic Diseases. 82. 1855–1855.

15.

Trentin, Francesca, Viola Signorini, Maria Laura Manca, et al.. (2023). Gender differences in SLE: report from a cohort of 417 Caucasian patients. Lupus Science & Medicine. 10(1). e000880–e000880. 13 indexed citations

16.

Andréoli, Laura, Micaela Fredi, Claudia Lomater, et al.. (2023). COVID-19 prognosis in systemic lupus erythematosus compared with rheumatoid arthritis and spondyloarthritis: results from the CONTROL-19 Study by the Italian Society for Rheumatology. Lupus Science & Medicine. 10(2). e000945–e000945. 2 indexed citations

17.

Signorini, Viola, Chiara Tani, Elena Elefante, et al.. (2021). How do systemic lupus erythematosus patients with very-long disease duration present? Analysis of a monocentric cohort. Lupus. 30(3). 439–447.

18.

Sciascia, Savino, Dario Roccatello, Massimo Radin, et al.. (2021). Differentiating between UCTD and early-stage SLE: from definitions to clinical approach. Nature Reviews Rheumatology. 18(1). 9–21. 33 indexed citations

19.

Saccon, Francesca, Margherita Zen, Mariele Gatto, et al.. (2020). Remission in systemic lupus erythematosus: testing different definitions in a large multicentre cohort. Annals of the Rheumatic Diseases. 79(7). 943–950. 29 indexed citations

20.

Talarico, Rosaria, Stefano Bombardieri, Gerd R Burmester, et al.. (2020). Clinical practice guidelines adherence, knowledge and awareness in rare and complex connective tissue diseases across Europe: results from the first ERN ReCONNET survey. RMD Open. 6(2). e001344–e001344. 8 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact